Palleon and Shanghai Henlius Biotech link on autoimmune therapy

Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s sialidase enzyme therapeutic, E-602, to treat autoimmune diseases.
( read original story …)

---